291 related articles for article (PubMed ID: 16640524)
1. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
Taylor AL; Bowles KM; Callaghan CJ; Wimperis JZ; Grant JW; Marcus RE; Bradley JA
Transplantation; 2006 Aug; 82(3):375-81. PubMed ID: 16906036
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
Orjuela M; Gross TG; Cheung YK; Alobeid B; Morris E; Cairo MS
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
[TBL] [Abstract][Full Text] [Related]
8. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
[TBL] [Abstract][Full Text] [Related]
9. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
11. Novel treatment with rituximab of oropharyngeal posttransplant lymphoproliferative disorder after heart transplantation.
Kaczmarek I; Beiras-Fernandez A; Sadoni S; Bengel D; Deutsch MA; Meiser B; Reichart B
Exp Clin Transplant; 2005 Dec; 3(2):381-4. PubMed ID: 16417448
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
13. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.
Fischer A; Blanche S; Le Bidois J; Bordigoni P; Garnier JL; Niaudet P; Morinet F; Le Deist F; Fischer AM; Griscelli C
N Engl J Med; 1991 May; 324(21):1451-6. PubMed ID: 2023604
[TBL] [Abstract][Full Text] [Related]
14. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.
Gallego S; Llort A; Gros L; Sanchez de Toledo J; Bueno J; Moreno A; Nieto J; Sanchez de Toledo J
Pediatr Transplant; 2010 Feb; 14(1):61-6. PubMed ID: 19344338
[TBL] [Abstract][Full Text] [Related]
16. Early onset post-transplant lymphoproliferative disease is associated with allograft localization.
Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ; Homan van der Heide JJ; Veeger NJ; Kluin PM; Kluin-Nelemans HC
Clin Transplant; 2005 Jun; 19(3):327-34. PubMed ID: 15877793
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
18. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
19. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
Al-Akash SI; Al Makadma AS; Al Omari MG
Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
[TBL] [Abstract][Full Text] [Related]
20. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.
Raj R; Frost AE
J Heart Lung Transplant; 2005 Jun; 24(6):671-9. PubMed ID: 15949726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
